BRTXNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
BioRestorative Therapies, Inc.
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 14, 2026
$1.60+0.06 (+3.90%)
Close on Oct 19, 2026
- Market cap
- $28.36M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
93.4%
Operating margin
-4350.1%−775.9 pts over 5 years
Net margin
-3959.4%+10680.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -10.3% | +44.3% | +36.1% | -5.4% | |
| Gross profit | -9.9% | – | – | -0.9% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 193.9% | 159.8% | -320.5% | |
| Return on assets | -480.2% | -387.8% | -174.1% | |
| Current ratio | 0.01 | 3.05 | 0.84 | |
| Debt to equity | -0.06 | -3.21 | – | |
| Net debt to EBITDA | -0.04× | -0.46× | – | |
| Interest coverage | -804.3× | – | – | |
| Capex to revenue | 519.2% | – | 32.3% | |
| Diluted shares | 0M | 0M | 9M |
Where the cash went
Fiscal 2021 to 2025, five years combined
BioRestorative Therapies generated $34.69M from operations and spent $689.18K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$34.69M
Used
$689.18K
Capital expenditure$689.18K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-3959.4%
×Asset turnover0.04×
×Equity multiplier1.84×
=Return on equity, FY2025-320.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -3959.4% | 0.04× | 1.84× | -320.5% |
| FY2024 | -2239.2% | 0.03× | 1.34× | -96.9% |
| FY2023 | -7145.2% | 0.01× | 1.43× | -102.7% |
| FY2022 | -11037.0% | 0.01× | 1.85× | -125.5% |
| FY2021 | -96311.5% | 0.00× | 2.84× | -937.5% |
| FY2020 | -14639.9% | 0.03× | -0.41× | 159.8% |
| FY2019 | -11267.6% | 0.10× | -0.12× | 136.8% |
| FY2018 | -11277.3% | 0.08× | -0.19× | 161.8% |
| FY2017 | -11660.1% | 0.05× | -0.28× | 159.6% |
| FY2016 | -23755.4% | 0.02× | -0.40× | 193.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$14.24M
- Cash generatingOperating cash flow above zero-$10.79M
- Return on assets improvedROA up on the prior year-71.2% → -116.0%
- Earnings backed by cashOperating cash flow above net income-$10.79M vs -$14.24M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.97 → 0.84
- No dilutionShare count did not rise8M → 9M
- Gross margin improvedGross margin up on the prior year93.00% → 93.37%
- More efficientAsset turnover rose0.03 → 0.03